Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HRA Pharma UK

Bayer symbol

Bayer buoyant as new products drive pharma

Xarelto, Stivarga, Eylea and Xofigo all perform will in third quarter

- PMLiVE

EMA backs Lundbeck’s Brintellix in depression

Drug recommended for approval to treat major depressive episodes in adults

- PMLiVE

GSK sets up centre to develop greener drugs

Brazil centre to focus on sustainable chemistry

- PMLiVE

China weighs heavy on GSK figures in Q3

Pharma company loses two thirds of sales in region after scandal-hit period

- PMLiVE

GSK and Genmab file Arzerra for first-line use in US

Plans progress to expand the chronic lymphocytic leukaemia drug

- PMLiVE

Michael J Fox Foundation backs Lundbeck projects

Will fund Parkinson’s disease research

ABPI London offices

ABPI announces review of Code

Trade body to update standards for pharma industry in UK

- PMLiVE

Lundbeck and Otsuka take Alzheimer’s drug into phase III

Lu AE58054 affects levels of serotonin in the brain

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

- PMLiVE

Bayer gets US nod for first-in-class Adempas

FDA clears drug for use in pulmonary artery hypertension

Bayer symbol

Bayer expects five drugs to enter phase III in 2015

Hopes to follow success of recent launches

- PMLiVE

GSK hoping to file malaria vaccine next year

New phase III data backs submission plans

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links